glucagon-like peptide-1 agonist

Overview

glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of pharmacological therapies that mimic the action of the endogenous incretin hormone glucagon-like peptide-1 (GLP-1), a peptide secreted primarily by intestinal L-cells in response to nutrient ingestion. By binding to and activating the GLP-1 receptor — a G protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, the heart, the kidneys, and other tissues — these agents stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. Their mechanism of action is therefore both peripheral and central, producing coordinated effects on glycaemic control and energy homeostasis. Major approved agents in this class include liraglutide, semaglutide (available in both subcutaneous and oral formulations), and exenatide, as well as dual-agonist compounds such as tirzepatide, which simultaneously targets the glucose-dependent insulinotropic polypeptide (GIP) receptor alongside the GLP-1 receptor.

Beyond their original indication in type 2 diabetes, GLP-1 RAs have emerged as transformative therapies for obesity, cardiovascular disease, and a growing number of cardiometabolic comorbidities. Their pleiotropic effects — encompassing anti-inflammatory, neuroprotective, hepatoprotective, and renoprotective properties — have motivated a rapid expansion of research into new disease areas, including metabolic dysfunction-associated steatotic liver disease (MASLD), Alzheimer's disease, pulmonary arterial hypertension, and oncology. The class is increasingly studied in combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors to characterize comparative effectiveness and potential synergistic benefits across organ systems.

Focus of Latest Publications

Recent publications have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) continue to yield measurable benefits across established indications, with multiple real-world studies confirming superior glycemic control compared with dipeptidyl peptidase-4 inhibitors and documented improvements in cardiovascular outcomes, mortality reduction, and healthcare utilization in type 2 diabetes. Comparative effectiveness studies have evaluated GLP-1RAs against sodium-glucose cotransporter-2 inhibitors (SGLT2i) in various populations, including patients with metabolic dysfunction-associated steatotic liver disease (MASLD), obese individuals, and those with renal impairment, with emerging evidence supporting combination therapy with SGLT2i for synergistic benefits in liver fibrosis progression and cardiovascular-kidney-metabolic syndrome. Research has also documented the economic burden and cost-effectiveness of GLP-1RA treatment, with findings indicating variable real-world persistence compared to trial-based efficacy and mixed evidence on long-term cost offsets depending on patient populations and comorbidities.

Expanding beyond traditional diabetes and obesity indications, recent studies have evaluated GLP-1RAs in Crohn's disease with comorbid obesity, where initiation was associated with lower mortality, reduced hospitalization rates, and decreased healthcare utilization over five-year follow-up, along with anti-inflammatory effects that warrant prospective investigation. Novel therapeutic applications have emerged, including hemodynamic improvements in pulmonary arterial hypertension with exenatide infusion, reduced postoperative surgical complications in dermatologic procedures, and mechanistic evidence that semaglutide, tirzepatide, and liraglutide inhibit amyloid-β42 aggregation with potential implications for Alzheimer's disease prevention. Additional investigational uses span obstructive sleep apnea with cardiovascular outcomes, bladder cancer survival, visceral adiposity in people living with HIV, and fragility fracture risk in older adults, reflecting a shift toward evaluating GLP-1RAs across multiple organ systems.

Special populations have received attention in recent literature, including kidney transplant recipients who demonstrated sustained weight loss, HbA1c reduction, and major adverse cardiovascular event reductions over five years with stable renal function, Hispanic adults with type 2 diabetes showing superior glycemic control with GLP-1RA monotherapy, adolescents with obesity achieving higher adherence when combined with behavioral health and lifestyle therapy, and cancer patients with active malignancy experiencing reduced all-cause mortality and hospitalization. Formulation innovation has progressed with pullulan-based bilayer films for non-injectable buccal delivery of GLP-1RA peptide analogues, addressing the clinical challenge of improving patient access to peptide therapeutics beyond injectable administration.

Key Publications

• NEWJul Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic Surgery. (JAMA network open, 2026, PMID 42384380): "Bariatric metabolic surgery (BMS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective interventions, but their long-term impact on health care utilization costs remains incompletely understood."
• NEWJul Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study. (Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026, PMID 42387223): "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated potential in reducing cardiovascular risk and improving OSA severity."
• NEWJun GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study. (Scientific reports, 2026, PMID 42321339): "GLP-1 receptor agonists (GLP-1RAs) have pleiotropic anti-inflammatory effects, yet their clinical impact in CD with comorbid obesity is incompletely characterized."
• NEWJun The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. (Bioscience reports, 2026, PMID 42307179): "The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists represents a watershed moment, fundamentally reshaping the therapeutic landscape for both T2D and obesity due to multifaceted metabolic benefits."
• Jun Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study. (Pediatric obesity, 2026, PMID 42222894): "Evidence for the role of health behaviour and lifestyle treatment (HBLT) on the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in paediatric obesity is limited."
• Jun Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients. (Urologic oncology, 2026, PMID 42224918): "To evaluate whether exposure to glucagon-like peptide-1 receptor agonists (GLP-1) or sodium-glucose cotransporter 2 inhibitors (SGLT2) is associated with overall survival (OS) in adults with treated bladder cancer."
• Jun GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study. (Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2026, PMID 42210885): "Glucagon-like peptide-1 (GLP) receptor agonists have demonstrated anti-inflammatory and wound-healing properties, but their impact on outcomes after dermatologic surgery has not been evaluated."
• May Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension. (JCI insight, 2026, PMID 42171611): "This first-in-disease study evaluated acute hemodynamic effects of GLP-1 agonist, exenatide administered i.v. in patients with idiopathic PAH and CTEPH as well as in a PAH rodent model."
• Jun ICER report demonstrates both the value and challenges in financing of weight loss medications. (Journal of managed care & specialty pharmacy, 2026, PMID 42166309): "Recent glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, demonstrate significant weight loss and cardiometabolic benefits and were found by the Institute for Clinical and Economic Review (ICER) to be cost-effective compared with lifestyle modifications alone."
• May Steatotic liver disease and cardiovascular-kidney-metabolic syndrome: A case study. (Nursing, 2026, PMID 42144672): "Incretin therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and gastric inhibitory polypeptide/GLP-1 receptor agonists are emphasized, due to their systemic benefits."